ATH434 for Multiple System Atrophy

Overseen By Alterity Clinical Trials

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Alterity Therapeutics

Disqualifiers: Neurological disorder, Unstable illness, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

10 Participants Needed

Trial Summary

What is the purpose of this trial?

This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy

Eligibility Criteria

This trial is for individuals with Multiple System Atrophy (MSA), showing symptoms like parkinsonism, low blood pressure upon standing, bladder issues, ataxia or abnormal muscle coordination, and certain signs on a neurological exam. They must have MSA biomarkers in their body fluids and MRI scans. People can't join if they can't swallow pills, attend visits, have brain structure issues on MRI, unstable health conditions or other significant neurological disorders.

Inclusion Criteria

I experience dizziness when standing up or have bladder control issues.

I show symptoms similar to Parkinson's disease.

I have coordination issues or muscle weakness.

Exclusion Criteria

You have a brain abnormality shown on an MRI.

I do not have any unstable medical or mental health conditions.

I cannot swallow pills.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive ATH434 to assess safety and efficacy

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• ATH434

Trial Overview The study is testing the safety and effectiveness of a drug called ATH434 in people who are clinically diagnosed with Multiple System Atrophy. It aims to see how well this drug works and what effects it has on patients' bodies.

Participant Groups

Group I: ATH434 Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Alterity Therapeutics

Lead Sponsor

Trials

3

Recruited

100+